Teva Pharma Industries Ltd ADR (TEVA)
Teva Pharma Industries Ltd ADR (TEVA) carries a ŷRobot AI score of 61 out of 100. The model's fair value estimate is $40.83, 8.3% below the last close of $44.50. The chart signal reads Sell.
| Metric | TEVA |
|---|---|
| AI score | 61 / 100 |
| Chart signal | Sell |
| Fair value estimate | $40.83 |
| Upside to fair value | -8.3% |
| Previous close | $44.50 |
| P/E | 97.16 |
| Price / sales | 2.89 |
| Market cap | $51.07B |
| EPS | 0.43 |
| Revenue growth | 4.8% |
| 1-year price change | 27.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about TEVA
Is TEVA overvalued or undervalued right now?
As of Nov 7, 2026, ŷRobot's fair-value model estimates Teva Pharma Industries Ltd ADR (TEVA) at $40.83 against a last close of $44.50, implying 8.3% downside to the model's estimate.
Is TEVA's chart signal bullish or bearish?
The chart-signal model classifies TEVA as Neutral as of Nov 14, 2026, with a signal score of -0.13 on a -1 to 1 scale.
What is TEVA's ŷRobot AI score?
TEVA scores 61 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 14, 2026.
Is TEVA stock expensive on P/E and P/S?
TEVA trades at 97.2 times earnings and 2.9 times sales as of Nov 14, 2026.
What does TEVA's seasonal forecast show?
ŷRobot's seasonal forecast curve for TEVA reads +8.2% at 30 days, +21.4% at 90 days, and +27.6% at one year as of Nov 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is TEVA growing?
Teva Pharma Industries Ltd ADR's revenue growth is +4.8% and free-cash-flow growth is -3.8% on the latest reported figures.
TEVA chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.